Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 5Breast 5Sarcoma 4Other hematologic neoplasm 4Gastrointestinal 4Thoracic 3Myeloid 3Genitourinary 3Head & Neck 2Gynecologic 2Lymphoid 1Classical hematology 1

Conditions

Stomach Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1Lung Neoplasms 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1

Interventions

Paclitaxel 575Carboplatin 520Cisplatin 347Bevacizumab 252pembrolizumab 226Gemcitabine 157Topotecan 128liposomal doxorubicin 127Cyclophosphamide 126olaparib 120Taxes 113Radiotherapy 110Docetaxel 94Brachytherapy 89Doxorubicin 84Drug Therapy 80niraparib 75Nivolumab 71Magnetic Resonance Spectroscopy 71Specimen Handling 65fludarabine 56Biopsy 55Hyperthermic Intraperitoneal Chemotherapy 53Filgrastim 52Letrozole 50Oxaliplatin 48durvalumab 47Immunoglobulin G 47atezolizumab 46Platinum 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × lonafarnib × Gynecologic × Clear all
NCT00539968 2015-02-05

A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED)

Merck Sharp & Dohme LLC

Phase 1/2 Terminated
5 enrolled
BreastGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT00281515 2012-06-29

Comparison of Paclitaxel/Carboplatin and Lonafarnib to Paclitaxel/Carboplatin for First-line Treatment of Ovarian Cancer

AGO Study Group

Phase 2 Completed
105 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡